The development of clinically relevant artificial intelligence (AI) models has traditionally required access to extensive labelled datasets, which inevitably centre AI advances around large centres and private corporations. Data availability has also dictated the development of AI applications: most studies focus on common cancer types, and leave rare diseases behind. However, this paradigm is changing with the advent of foundation models, which enable the training of more powerful and robust AI systems using much smaller datasets.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Chen, R. J. et al. Towards a general-purpose foundation model for computational pathology. Nat. Med. 30, 850–862 (2024).
Wagner, S. J. et al. Transformer-based biomarker prediction from colorectal cancer histology: a large-scale multicentric study. Cancer Cell 41, 1650–1661.e4 (2023).
Vaidya, A. et al. Demographic bias in misdiagnosis by computational pathology models. Nat. Med. 30, 1174–1190 (2024).
Wang, X. et al. Transformer-based unsupervised contrastive learning for histopathological image classification. Med. Image Anal. 81, 102559 (2022).
Vorontsov, E. et al. A foundation model for clinical-grade computational pathology and rare cancers detection. Nat. Med. https://doi.org/10.1038/s41591-024-03141-0 (2024).
Lu, M. Y. et al. A multimodal generative AI copilot for human pathology. Nature https://doi.org/10.1038/s41586-024-07618-3 (2024).
Derraz, B. et al. New regulatory thinking is needed for AI-based personalised drug and cell therapies in precision oncology. NPJ Precis. Oncol. 8, 23 (2024).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.N.K. has acted as a consultant and/or adviser of AstraZeneca, Bioptimus, DoMore Diagnostics, Mindpeak, MultiplexDx, Owkin, Panakeia and Scailyte; has received speaker’s fees from AstraZeneca, Bayer, BMS, Daiichi Sankyo, Eisai, Fresenius, GSK, Janssen, MSD, Pfizer and Roche; and holds shares in StratifAI, and Synagen. J.L. declares no competing interests.
Rights and permissions
About this article
Cite this article
Lipkova, J., Kather, J.N. The age of foundation models. Nat Rev Clin Oncol (2024). https://doi.org/10.1038/s41571-024-00941-8
Published:
DOI: https://doi.org/10.1038/s41571-024-00941-8
